Literature DB >> 16942572

The importance of IgE antibody levels in anti-IgE treatment.

S G O Johansson1, H Oman, A Nopp, S Pettersson.   

Abstract

BACKGROUND: Dosages of anti-immunoglobulin (Ig)E in treatment of allergic asthma is based on total IgE body pool assuming that IgE antibodies responsible for the disease are evenly distributed among patients. This assumption was evaluated.
METHODS: Median and quartile concentrations of IgE and IgE antibodies to cat and mite in 6461 sera submitted to an allergy laboratory during 2003-2005 were calculated and expressed in groups of different IgE levels.
RESULTS: Of 3872 (60%) samples from adults with a serum IgE level of 30-700 kU/l, 22.2% had IgE antibodies (>or=0.35 kU(A)/l) to mite, 36.0% to cat and 8.1% to both. The relative concentration of IgE antibody of IgE decreased with increasing IgE, indicating a more specific response in patients with slightly elevated serum IgE. At a hypothetical serum IgE level of 10 kU/l, the threshold recommended for anti-IgE treatment, 25% of the originally mite- and/or cat-positive population in the <75 kU/l IgE group still would have detectable IgE antibodies.
CONCLUSIONS: Sera from patients sensitized to mite and cat with moderate serum IgE levels have a high proportion of IgE antibodies; in the 30-74 kU/l group, as much as 10% of the IgE could be specific to one allergen. An increase of the anti-IgE dosage given to such patients should be considered, especially because IgE antibodies with different, relevant specificities have an additive effect in triggering inflammatory cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942572     DOI: 10.1111/j.1398-9995.2006.01172.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  9 in total

Review 1.  Assessing basophil functional measures during monoclonal anti-IgE therapy.

Authors:  Sarbjit S Saini; Donald W MacGlashan
Journal:  J Immunol Methods       Date:  2012-06-01       Impact factor: 2.303

Review 2.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 3.  The History of IgE: From discovery to 2010.

Authors:  S G O Johansson
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

Review 4.  IgE antibody-specific activity in human allergic disease.

Authors:  Robert G Hamilton; Donald W MacGlashan; Sarbjit S Saini
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

5.  Small, mobile FcepsilonRI receptor aggregates are signaling competent.

Authors:  Nicholas L Andrews; Janet R Pfeiffer; A Marina Martinez; David M Haaland; Ryan W Davis; Toshiaki Kawakami; Janet M Oliver; Bridget S Wilson; Diane S Lidke
Journal:  Immunity       Date:  2009-09-10       Impact factor: 31.745

Review 6.  Systemic Treatment of Adult Atopic Dermatitis: A Review.

Authors:  Matteo Megna; Maddalena Napolitano; Cataldo Patruno; Alessia Villani; Anna Balato; Giuseppe Monfrecola; Fabio Ayala; Nicola Balato
Journal:  Dermatol Ther (Heidelb)       Date:  2016-12-26

7.  A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.

Authors:  S Gunnar O Johansson; Gunnar Lilja; Jenny Hallberg; Anna Nopp
Journal:  Immun Inflamm Dis       Date:  2018-05-07

Review 8.  Basophil Activation Test: Old and New Applications in Allergy.

Authors:  Oliver Hemmings; Matthew Kwok; Richard McKendry; Alexandra F Santos
Journal:  Curr Allergy Asthma Rep       Date:  2018-11-15       Impact factor: 4.806

9.  A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.

Authors:  E Suzanne Cohen; Claire L Dobson; Helena Käck; Bing Wang; Dorothy A Sims; Christopher O Lloyd; Elizabeth England; D Gareth Rees; Hongwei Guo; Sophia N Karagiannis; Siobhan O'Brien; Sofia Persdotter; Helena Ekdahl; Robin Butler; Feenagh Keyes; Sarah Oakley; Mats Carlsson; Emmanuel Briend; Trevor Wilkinson; Ian K Anderson; Phillip D Monk; Karin von Wachenfeldt; Per-Olof F Eriksson; Hannah J Gould; Tristan J Vaughan; Richard D May
Journal:  MAbs       Date:  2014-02-28       Impact factor: 5.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.